As Group General Counsel and a member of the Executive Committee, led Actelion’s legal department for 17 years from its startup phase until its acquisition by Johnson & Johnson in 2017. Thereafter, held interim positions as Group General Counsel/Chief Legal Officer with Idorsia Pharmaceuticals AG (March – October 2022) and at Swiss Rockets AG/Rocketvax AG (May – July 2021). Mr. Borovsky holds a doctorate in law, is an attorney-at-law and a qualified business mediator.

Former Chairman of the board of directors of Curatis (2012-April 2024) and Curatis’ Chief Executive Officer (until 2011). Held various commercial management positions at Speciality European Pharma (now Contura), MyoContract (now Santhera Pharmaceuticals), Hoffmann-La Roche in Switzerland, USA, and Latin America. Graduated with a “Maîtrise Administration Économique et Sociale” from the University of Lyon, France and a “lic.oec.int” in International Economic Relations from the University of Constance, Germany.

Dr. Silvio Inderbitzin is a member of the Board of Directors and shareholder of Curatis. Dr. Inderbitzin has held multiple senior positions in the pharmaceutical industry during the last 20 years. With his origin in pharmaceutical manufacturing, he also served as Head of Quality Assurance and was responsible for product release as a Qualified Person at Spirig Pharma AG. He was later elected to the position of Technical Director of Spirig Pharma AG and served in the Corporate Management Team, ultimately joining the board of directors and becoming co-owner of the privately held 450 employee company. Prior to the successful sale of the Spirig Pharma AG, he served as CEO and was responsible for its foreign subsidiaries. He is an active investor and board member of several life science and MedTech companies as well as startups. Dr. Inderbitzin studied pharmacy at the University of Berne, holds a Ph.D. in Pharmacology from the University of Zurich/ETH, and obtained an Executive MBA from the University of St. Gallen.

Board member of Curatis AG and former Chief Executive Officer of Curatis (2012-2019). Previously he held positions as Vice President/General Manager at Orphan Europe in Paris France and was in this function member of the Executive Management of Recordati Group (Milan, Italy), and was Regional Vice President/General Manager and Vice President Strategic Marketing Europe at Actelion. Mr. Rutschmann also held various management positions in marketing and sales for Hoffmann-La Roche and Warner-Lambert in Switzerland, the Netherlands and Germany. Mr. Rutschmann holds a PhD in cell biology/immunology from the University of Basle and completed management programs at INSEAD.

Board member of Curatis AG and former Chief Executive Officer of Curatis (2012-2019). Previously he held positions as Vice President/General Manager at Orphan Europe in Paris France and was in this function member of the Executive Management of Recordati Group (Milan, Italy), and was Regional Vice President/General Manager and Vice President Strategic Marketing Europe at Actelion. Mr. Rutschmann also held various management positions in marketing and sales for Hoffmann-La Roche and Warner-Lambert in Switzerland, the Netherlands and Germany. Mr. Rutschmann holds a PhD in cell biology/immunology from the University of Basle and completed management programs at INSEAD.

Former Chairman of the board of directors of Curatis (2012-April 2024) and Curatis’ Chief Executive Officer (until 2011). Held various commercial management positions at Speciality European Pharma (now Contura), MyoContract (now Santhera Pharmaceuticals), Hoffmann-La Roche in Switzerland, USA, and Latin America. Graduated with a “Maîtrise Administration Économique et Sociale” from the University of Lyon, France and a “lic.oec.int” in International Economic Relations from the University of Constance, Germany.

Former Chief Executive Officer at Curatis AG (2019-Arpil 2024). Previously General Manager at Alexion Pharma International (GmbH), held various commercial & marketing management lead positions at Roche Pharma, Sanofi-Aventis and Caris Life Sciences. More than 25 years of experience in the Life Sciences & Biotechnology industry at national and international levels (Germany, France, Austria, Greece, Israel, Republic of South Africa). Focus on (ultra) rare diseases & oncology. Expertise in strategic & operational marketing, market access and P&R. Educated as a pharmacist, holds a Master’s Degree in Marketing, graduated from INSEAD Marketing Champions Program.

Patrick Ramsauer is CFO of Curatis and a member of the executive management team. Previously he held various positions in Corporate Finance at UBS AG and as Founder and Portfolio Manager in RBR Capital, a Swiss Asset Management company, as well as in the technology sector with Palantir, a US based AI and data integration software company. He is CFO of a data integration company and Partner in Yuma Capital, a Swiss corporate finance advisory boutique. Patrick Ramsauer has more than 25 years of experience in finance, and holds a degree in Finance from the University of Zurich.

Stewart Goldman, MD, is an internationally renowned pediatric oncologist, Chair of the Department of Child Health at the University of Arizona College of Medicine, Phoenix, Arizona, Senior Vice President of Research at Phoenix Children’s’ and Sybil B Harrington Endowed Chair of Oncology. He oversees a research program that consists of over 700 studies. In his role leading the Department, Dr. Goldman and his team focus on translational research across all aspects of child and family health to innovate clinical care, advance new therapies for common and rare childhood diseases, and to improve the emotional, educational, and cognitive well-being of children. Dr. Goldman joined Phoenix Children’s after an illustrious 23-year tenure at Ann and Robert H. Lurie Children’s Hospital of Chicago and Northwestern University Feinberg School of Medicine, where he served as the Division Head of Hematology-Oncology, Neuro-Oncology and Stem Cell Transplantation and as a professor of Pediatrics. An accomplished leader in brain tumor research, Dr. Goldman’s contributions to the medical and scientific communities are significant. He’s published more than 170 peer-reviewed articles. Dr. Goldman earned his medical degree from Loyola University Stitch School of Medicine and completed his internship, residency, and fellowship at the University of Chicago Hospital.

Prof. Andreas Gantenbein started his career as clinical research fellow in the Headache Group of Peter Goadsby at Queen Square, London. The main research focus was on electrophysiological correlates in migraine. Following his return to Switzerland he started a broad clinical training in neurology, including electroencephalography, electroneuromyography, sleep diagnostics and pain medicine. From 2010 to 2012 he was head of the Headache and Pain Unit at the University Hospital of Zurich. From 2012 he continued his research and clinical work at the rehabilitation center RehaClinic Bad Zurzach, from 2014 until 2021 as the Chief Physician of Neurology. In 2021 he started is private practice in Bülach and still works as Medical Advisor at the Reha ClinicBad Zurzach.  Andreas Gantenbein is former president of the Swiss Headache Society. His main research focus lies in clinical studies, including medication overuse headache, menstrual migraine, and CGRP-antibodies. He has published more than 100 articles in peer-reviewed journals.

Dr. Anthony Man, B.Med Sci, MB, BS, FRCP (UK), was originally trained in internal medicine and oncology physician and currently serves as an independent consultant in drug development to Biotechnology companies as well as to NGOs in Global Health. He has over 35 years of experience in international clinical research and drug development through all clinical stages of new drug development from Investigational New Drug to Life Cycle Management in multiple therapeutic areas including oncology, infectious disease, rheumatology, metabolic disease, respiratory, cardiovascular, ophthalmology and transplantation medicine. He has contributed to over 30 successful new drug applications and has held International senior management positions in large pharma organizations including Lederle, Roche, Ciba Geigy and Novartis. He also served from 2000-2013 as Chief Development Officer and Chief Executive Officer of Basilea Pharmaceutica, a successful public Swiss biotech company.

Arnim Pause, M.Sc., Ph.D., is a Professor of Biochemistry at McGill University’s Goodman Cancer Institute and the Department of Biochemistry in Montreal, Canada (2002–present). Arnim Pause is also Senior Director of Research at Kreamedica Inc.. He served as Clinical Project Manager (2011-2014) and Scientific Advisor at Curatis AG (2010–present). Prof.  Pause has authored over 90 high-impact peer reviewed publications, book chapters, and patents. He previously held leadership roles in R&D at Boehringer Ingelheim and the Max-Planck Institute for Biochemistry. His academic journey includes a B.Sc. and M.Sc. in Molecular Biology from the University of Konstanz, Germany, a Ph.D. in Biochemistry from McGill University, and a Fogarty/DFG fellowship at the National Cancer Institute (NCI) in the USA. His research expertise spans molecular medicine, with a focus on cancer biology, virology, and metabolic diseases, bridging both academic and industry settings.